drugset / Trial / NCT04335045
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study was to determine the safety and tolerability of PH100, a purified phlorotannins from a brown alga Ecklonia cava and the pharmacokinetics of its major compounds 8,8'-bieckol, dieckol, and phlorofucofuroeckol A (PFF-A), after single, ascending, oral doses of PH100 Capsules (over-encapsulated tablets) in healthy adult volunteers.
Timeline
- Start
- 2013-09-25
- Primary completion
- 2014-12-08
- Completion
- 2014-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PH100 | Unknown | 100 mg | Oral |
| Comparator | PH100 | Unknown | 200 mg | Oral |
| Comparator | PH100 | Unknown | 400 mg | Oral |
| Comparator | PH100 | Unknown | 800 mg | Oral |
| Comparator | PH100 | Unknown | 1200 mg | Oral |
| Comparator | PH100 | Unknown | 1600 mg | Oral |
Indications
No indication recorded.